BackgroundTumour-associated lymphocytes (TALs) have been linked with good prognosis in several solid tumours. This study aimed to evaluate the prognostic significance of CD3, CD8 and CD20 positive lymphocytes in pancreatic ductal adenocarcinoma.MethodsAfter histological re-evaluation of the tumours of 81 patients who underwent surgical resection for exclusively pancreatic ductal adenocarcinoma, tissue micro-arrays (TMA) were constructed and immunohistochemistry was performed for CD3, CD8 and CD20. The number of lymphocytes within specific tumour compartments (i.e. stromal and intratumoural) was quantified. X-tile software (Yale School of Medicine, CT, USA) was used to stratify patients into 'high’ and 'low’ for each of the lymphocytes stain...
Background & Aims: Changes to the microenvironment of pancreatic ductal adenocarcinomas (PDACs) have...
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor and is insensitive to radiothera...
Immunotherapeutic modalities are currently revolutionizing cancer treatment. In pancreatic cancer, h...
11siBackground: We investigated the correlation between pancreatic ductal adenocarcinoma patient pr...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
In patients with pancreatic ductal adenocarcinoma (PDAC), the tumor microenvironment consists of cel...
Among the subsets of tumor-infiltrating lymphocytes (TILs), activated cytotoxic T lymphocytes (granz...
Abstract Background Both activated tumor-infiltrating lymphocytes (TILs) and immune-suppressive cell...
This study aimed to elucidate the prognostic implications of intratumoral and peritumoral infiltrati...
International audienceAbstract Background The prognosis of patients with pancreatic cancer remains p...
The tumor microenvironment (TME) plays a vital role in the development, progression, and metastasis ...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
This work aims to evaluate the initial values and changes of peripheral blood lymphocytes during tre...
Background: Pancreatic ductal adenocarcinoma (PDAC) prognosis remains poor and novel therapeutic tar...
We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together w...
Background & Aims: Changes to the microenvironment of pancreatic ductal adenocarcinomas (PDACs) have...
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor and is insensitive to radiothera...
Immunotherapeutic modalities are currently revolutionizing cancer treatment. In pancreatic cancer, h...
11siBackground: We investigated the correlation between pancreatic ductal adenocarcinoma patient pr...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
In patients with pancreatic ductal adenocarcinoma (PDAC), the tumor microenvironment consists of cel...
Among the subsets of tumor-infiltrating lymphocytes (TILs), activated cytotoxic T lymphocytes (granz...
Abstract Background Both activated tumor-infiltrating lymphocytes (TILs) and immune-suppressive cell...
This study aimed to elucidate the prognostic implications of intratumoral and peritumoral infiltrati...
International audienceAbstract Background The prognosis of patients with pancreatic cancer remains p...
The tumor microenvironment (TME) plays a vital role in the development, progression, and metastasis ...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy in need of effecti...
This work aims to evaluate the initial values and changes of peripheral blood lymphocytes during tre...
Background: Pancreatic ductal adenocarcinoma (PDAC) prognosis remains poor and novel therapeutic tar...
We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together w...
Background & Aims: Changes to the microenvironment of pancreatic ductal adenocarcinomas (PDACs) have...
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor and is insensitive to radiothera...
Immunotherapeutic modalities are currently revolutionizing cancer treatment. In pancreatic cancer, h...